Abstract
Objectives:
This study aimed to explore the correlation between Fibroblast Growth Factor-23 (FGF23) levels and Cerebral Infarction (CI), and to determine whether there is a significant relationship between FGF23 and the occurrence and severity of CI.
Methods:
The study categorized Cerebral Infarction (CI) patients into severe and mild stenosis groups based on vertebrobasilar artery stenosis, using Digital Subtraction Angiography (DSA) and Magnetic Resonance Imaging (MRI). The study compared the levels of Fibroblast Growth Factor-23 (FGF23) in the serum of CI patients and healthy controls using a t-test and evaluated the diagnostic effectiveness of serum FGF23 using a Receiver Operating Characteristic (ROC) curve. Additionally, the study analyzed the correlation between FGF23 levels and CI severity after treatment using the National Institute of Health Stroke Scale score.
Results:
The study found a significant increase in serum Fibroblast Growth Factor-23 (FGF23) levels in patients with Cerebral Infarction (CI) compared to healthy volunteers, (p < 0.001). A higher serum FGF23 level was observed in the severe stenosis group than in the mild stenosis group (p < 0.001). Furthermore, the study showed that a high FGF23 level at admission was significantly related to more severe symptoms of CI as indicated by the National Institute of Health Stroke Scale (NIHSS) score on the 7th day after treatment (p < 0.001).
Conclusions:
This study discovered a correlation between Fibroblast Growth Factor-23 (FGF23) levels, vertebroba-silar artery stenosis, and short-term prognosis in patients who had recently experienced acute Cerebral Infarction (CI).
Keywords:
Fibroblast growth factor-23; Cerebral infarction; DSA; Stents; Vertebrobasilar artery stenosis
HIGHLIGHTS
A meta-analysis suggested that the risk for posterior-circulation stroke was roughly as high as the risk for anterior-circulation stroke. At the same time, the authors found that it was difficult to identify VBI upon routine physical examination with modalities such as carotid artery ultrasonography. The aim of this study was to investigate the possibility of FGF23 as a rapid biomarker for risk stratification of patients with acute CI and screen patients at high risk of CI.
The study assessed the characteristics of patients with CI and found that the severity of VBI was a significant factor. Furthermore, serum FGF23 levels were significantly higher in patients with CI and significantly associated with NIHSS score on the 7th day after diagnosis. It is suggested that serum FGF23 level at admission may be a predictor of short-term outcomes in patients with CI.
In the present study, FGF23 was a potential diagnostic indicator of CI with 79.8 % sensitivity and 80.3 % specificity. The ROC curve results indicated that serum FGF23 levels are a potential diagnostic biomarker for CI.
This study provides important insights into the potential clinical utility of FGF23 as a diagnostic biomarker for CI and VBI.
Thumbnail
Thumbnail
Thumbnail
